Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | EVP Chief R&D | March 04, 2026 | March 06, 2026 |
| SQZ Biotechnologies CoSQZ · Entity 112267 | Director | June 14, 2023 | June 15, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date March 04, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,693 |
Ending reported balance
After 2026-03-05 transaction · row 12
12 source rows · reconciled sequenceRow 1 · 2026-03-04 · Sale · Disposed 106 · Balance 23,300 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 2 · 2026-03-04 · Sale · Disposed 102 · Balance 23,198 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2026-03-04 · Sale · Disposed 215 · Balance 22,983 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2026-03-04 · Sale · Disposed 289 · Balance 22,694 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2026-03-04 · Sale · Disposed 350 · Balance 22,344 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2026-03-04 · Sale · Disposed 767 · Balance 21,577 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 7 · 2026-03-04 · Sale · Disposed 272 · Balance 21,305 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 8 · 2026-03-04 · Sale · Disposed 208 · Balance 21,097 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 9 · 2026-03-05 · Sale · Disposed 654 · Balance 20,443 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F11: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.03 to $322.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 10 · 2026-03-05 · Sale · Disposed 740 · Balance 19,703 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F12: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.09 to $324.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 11 · 2026-03-05 · Sale · Disposed 510 · Balance 19,193 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F13: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.26 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 12 · 2026-03-05 · Sale · Disposed 500 · Balance 18,693 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F14: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.67 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 431 |
Reported balance
Holding disclosure · report date 2026-03-04 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 431 F15: Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 250 |
Reported balance
Holding disclosure · report date 2026-03-04 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 250 F16: Represents shares held in trust, of which the Reporting Persons spouse is co-trustee. The Reporting Person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.
F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025.
F11: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.03 to $322.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F12: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.09 to $324.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F13: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.26 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F14: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.67 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F15: Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
F16: Represents shares held in trust, of which the Reporting Persons spouse is co-trustee. The Reporting Person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
SQZ Biotechnologies Co
Report date June 14, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2033-06-13 | Direct | 39,875 |
Reported balance
After 2023-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 39,875 · Balance 39,875 F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2025 Filed Mar 5, 2025 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 147 | $239.25 | $35,169.75 |
DisclosureSEC source: 0001735276-25-000032 · edgardoc.xml · nonDerivative · entry 12 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,203 F10 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $238.93 to $239.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 7,819 | $0.00 Strike: $243.53 | $0.00 |
DisclosureSEC source: 0001735276-25-000032 · edgardoc.xml · derivative · entry 18 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,819 Underlying: Common Stock · 7,819 shares Expires 2035-03-03 F20 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 117 | $245.53 | $28,727.01 |
DisclosureSEC source: 0001735276-25-000032 · edgardoc.xml · nonDerivative · entry 11 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,350 F10 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $245.07 to $245.74. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 273 | $244.43 | $66,729.39 |
DisclosureSEC source: 0001735276-25-000032 · edgardoc.xml · nonDerivative · entry 10 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,467 F10 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $244.04 to $244.80. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 583 | $243.13 | $141,744.79 |
DisclosureSEC source: 0001735276-25-000032 · edgardoc.xml · nonDerivative · entry 9 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,740 F10 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.62 to $243.58. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1 | $248.36 | $248.36 |
DisclosureSEC source: 0001735276-25-000032 · edgardoc.xml · nonDerivative · entry 8 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,323 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 5 | $247.35 | $1,236.75 |
DisclosureSEC source: 0001735276-25-000032 · edgardoc.xml · nonDerivative · entry 7 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,324 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $247.04 to $247.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 48 | $246.18 | $11,816.64 |
DisclosureSEC source: 0001735276-25-000032 · edgardoc.xml · nonDerivative · entry 6 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,329 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $246.00 to $246.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 116 | $245.26 | $28,450.16 |
DisclosureSEC source: 0001735276-25-000032 · edgardoc.xml · nonDerivative · entry 5 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,377 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $244.91 to $245.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 158 | $244.41 | $38,616.78 |
DisclosureSEC source: 0001735276-25-000032 · edgardoc.xml · nonDerivative · entry 4 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,493 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $243.90 to $244.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 235 | $243.36 | $57,189.60 |
DisclosureSEC source: 0001735276-25-000032 · edgardoc.xml · nonDerivative · entry 3 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,651 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.89 to $243.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 213 | $242.37 | $51,624.81 |
DisclosureSEC source: 0001735276-25-000032 · edgardoc.xml · nonDerivative · entry 2 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,886 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.87 to $242.86. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 14,137 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000032 · edgardoc.xml · nonDerivative · entry 1 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,099 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. F2 · balance_after: The Reporting Person has reported certain prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 14,137 newly awarded RSUs and 10,405 shares of common stock. The Reporting Person also holds 1,908 unvested RSUs that were previously reported in Table II. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 69 | $244.11 | $16,843.59 |
DisclosureSEC source: 0001735276-25-000020 · edgardoc.xml · nonDerivative · entry 9 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,962 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $243.90 to $244.32. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 142 | $243.23 | $34,538.66 |
DisclosureSEC source: 0001735276-25-000020 · edgardoc.xml · nonDerivative · entry 8 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,031 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.87 to $243.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 352 | $242.44 | $85,338.88 |
DisclosureSEC source: 0001735276-25-000020 · edgardoc.xml · nonDerivative · entry 7 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,173 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.86 to $242.86. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 149 | $241.51 | $35,984.99 |
DisclosureSEC source: 0001735276-25-000020 · edgardoc.xml · nonDerivative · entry 6 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,525 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $240.85 to $241.85. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 91 | $240.32 | $21,869.12 |
DisclosureSEC source: 0001735276-25-000020 · edgardoc.xml · nonDerivative · entry 5 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,674 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $239.82 to $240.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 41 | $239.18 | $9,806.38 |
DisclosureSEC source: 0001735276-25-000020 · edgardoc.xml · nonDerivative · entry 4 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,765 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $238.73 to $239.69. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 40 | $238.33 | $9,533.20 |
DisclosureSEC source: 0001735276-25-000020 · edgardoc.xml · nonDerivative · entry 3 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,806 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $237.72 to $238.72. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 51 | $236.51 | $12,062.01 |
DisclosureSEC source: 0001735276-25-000020 · edgardoc.xml · nonDerivative · entry 2 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,846 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $236.50 to $237.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionRestricted Stock Units · Derivative | 1,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000020 · edgardoc.xml · derivative · entry 12 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,908 Underlying: Common Stock · 1,908 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_price: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. F13 · derivative.exercise_date: On February 27, 2023, the reporting person was granted 5,724 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2025, the second tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4. F13 · derivative.expiration_date: On February 27, 2023, the reporting person was granted 5,724 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2025, the second tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:31 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 1,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000020 · edgardoc.xml · nonDerivative · entry 1 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 18, 2025 21:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 80 | $259.10 | $20,728.00 |
DisclosureSEC source: 0001735276-25-000009 · edgardoc.xml · nonDerivative · entry 19 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,989 F13 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. Read SEC document |
| February 18, 2025 Filed Feb 18, 2025 21:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 107 | $257.99 | $27,604.93 |
DisclosureSEC source: 0001735276-25-000009 · edgardoc.xml · nonDerivative · entry 18 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,069 F13 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. F17 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $257.79 to $258.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 18, 2025 Filed Feb 18, 2025 21:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 83 | $256.05 | $21,252.15 |
DisclosureSEC source: 0001735276-25-000009 · edgardoc.xml · nonDerivative · entry 17 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,176 F13 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. F16 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $256.00 to $256.95. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 18, 2025 Filed Feb 18, 2025 21:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 110 | $251.60 | $27,676.00 |
DisclosureSEC source: 0001735276-25-000009 · edgardoc.xml · nonDerivative · entry 16 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,259 F13 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. Read SEC document |
| February 18, 2025 Filed Feb 18, 2025 21:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 306 | $250.73 | $76,723.38 |
DisclosureSEC source: 0001735276-25-000009 · edgardoc.xml · nonDerivative · entry 15 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,369 F13 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. F15 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $250.57 to $251.25. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 18, 2025 Filed Feb 18, 2025 21:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 862 | $250.11 | $215,594.82 |
DisclosureSEC source: 0001735276-25-000009 · edgardoc.xml · nonDerivative · entry 14 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,675 F13 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $249.56 to $250.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 32 | $264.87 | $8,475.84 |
DisclosureSEC source: 0001735276-25-000009 · edgardoc.xml · nonDerivative · entry 13 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,537 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 27 | $263.33 | $7,109.91 |
DisclosureSEC source: 0001735276-25-000009 · edgardoc.xml · nonDerivative · entry 12 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,569 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 60 | $261.45 | $15,687.00 |
DisclosureSEC source: 0001735276-25-000009 · edgardoc.xml · nonDerivative · entry 11 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,596 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $261.42 to $261.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 49 | $260.57 | $12,767.93 |
DisclosureSEC source: 0001735276-25-000009 · edgardoc.xml · nonDerivative · entry 10 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,656 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $260.31 to $260.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 27 | $259.72 | $7,012.44 |
DisclosureSEC source: 0001735276-25-000009 · edgardoc.xml · nonDerivative · entry 9 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,705 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $259.21 to $260.14. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 77 | $258.07 | $19,871.39 |
DisclosureSEC source: 0001735276-25-000009 · edgardoc.xml · nonDerivative · entry 8 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,732 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $257.86 to $258.44. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 60 | $257.51 | $15,450.60 |
DisclosureSEC source: 0001735276-25-000009 · edgardoc.xml · nonDerivative · entry 7 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,809 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $257.05 to $257.78. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 126 | $256.29 | $32,292.54 |
DisclosureSEC source: 0001735276-25-000009 · edgardoc.xml · nonDerivative · entry 6 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,869 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $256.01 to $256.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 110 | $255.56 | $28,111.60 |
DisclosureSEC source: 0001735276-25-000009 · edgardoc.xml · nonDerivative · entry 5 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,995 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $254.99 to $255.97. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 258 | $254.35 | $65,622.30 |
DisclosureSEC source: 0001735276-25-000009 · edgardoc.xml · nonDerivative · entry 4 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,105 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $253.96 to $254.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 386 | $253.37 | $97,800.82 |
DisclosureSEC source: 0001735276-25-000009 · edgardoc.xml · nonDerivative · entry 3 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,363 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $252.90 to $253.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 349 | $252.50 | $88,122.50 |
DisclosureSEC source: 0001735276-25-000009 · edgardoc.xml · nonDerivative · entry 2 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,749 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $251.89 to $252.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:47 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 3,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000009 · edgardoc.xml · nonDerivative · entry 1 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,098 F1 · kind: On February 24, 2021, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of four specified performance measures. The shares reported were issued to the reporting person upon vesting of one-quarter of the shares subject to the PSU based on the issuer publicly reporting achievement, on or before December 31, 2025, of non-GAAP operating income profitability for a 12-month calendar year, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on February 13, 2025. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 23,876 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-25-000004 · edgardoc.xml · derivative · entry 7 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,876 shares Expires 2025-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 11, 2024. The 48,876 options exercised and sold by the reporting person were due to expire on December 18, 2025. F5 · derivative.exercise_date: This stock option was fully vested and exercisable as of December 18, 2019. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionPerformance Stock Option 2015 (right to buy) · Derivative | 25,000 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-25-000004 · edgardoc.xml · derivative · entry 6 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 11, 2024. The 48,876 options exercised and sold by the reporting person were due to expire on December 18, 2025. F4 · derivative.exercise_date: This stock option was fully vested and exercisable as of August 6, 2019. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 52,592 | $285.00 | $14,988,720.00 |
DisclosureSEC source: 0001735276-25-000004 · edgardoc.xml · nonDerivative · entry 3 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,989 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 11, 2024. The 48,876 options exercised and sold by the reporting person were due to expire on December 18, 2025. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 25,000 | $88.95 | $2,223,750.00 |
DisclosureSEC source: 0001735276-25-000004 · edgardoc.xml · nonDerivative · entry 2 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 11, 2024. The 48,876 options exercised and sold by the reporting person were due to expire on December 18, 2025. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 23,876 | $88.95 | $2,123,770.20 |
DisclosureSEC source: 0001735276-25-000004 · edgardoc.xml · nonDerivative · entry 1 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 11, 2024. The 48,876 options exercised and sold by the reporting person were due to expire on December 18, 2025. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1 | $255.80 | $255.80 |
DisclosureSEC source: 0001735276-24-000110 · edgardoc.xml · nonDerivative · entry 7 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,705 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 140 | $254.37 | $35,611.80 |
DisclosureSEC source: 0001735276-24-000110 · edgardoc.xml · nonDerivative · entry 6 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,706 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $254.35 to $255.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 100 | $252.94 | $25,294.00 |
DisclosureSEC source: 0001735276-24-000110 · edgardoc.xml · nonDerivative · entry 5 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,846 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.